Studies have shown that neoadjuvant nivolumab may provide long-term benefits for people with non-small cell lung cancer.

Published Date: 17 Feb 2023

BACKGROUND: NSCLC is the most common and important cause of cancer worldwide. Assessment: The patient...

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Weight-Based and Fixed-Dose Pembrolizumab Compared in NSCLC

2.

Chemotherapy combination boosts overall survival in patients with EGFR-mutant non-small cell lung cancer

3.

Global warming could be driving up women's cancer risk, find researchers

4.

Universal screening approach achieves a comparable detection rate of lung cancer

5.

Quality of Life Similar With Proton Beam Therapy vs IMRT for Prostate Cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot